Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.2 USD | -0.54% | +13.02% | +41.54% |
Apr. 30 | RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating | MT |
Apr. 29 | Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024 |
Financials (USD)
Sales 2024 * | 139M | Sales 2025 * | 164M | Capitalization | 584M |
---|---|---|---|---|---|
Net income 2024 * | -20M | Net income 2025 * | -11M | EV / Sales 2024 * | 4.2 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.56 x |
P/E ratio 2024 * |
-29
x | P/E ratio 2025 * |
-49.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.93% |
Latest transcript on Avid Bioservices, Inc.
1 day | -0.54% | ||
1 week | +9.79% | ||
Current month | +20.58% | ||
1 month | +35.29% | ||
3 months | +19.48% | ||
6 months | +75.24% | ||
Current year | +41.54% |
Managers | Title | Age | Since |
---|---|---|---|
Nicholas Green
CEO | Chief Executive Officer | 60 | 20-07-29 |
Daniel Hart
DFI | Director of Finance/CFO | 50 | 18-07-31 |
Nick Ferguson
CTO | Chief Tech/Sci/R&D Officer | - | 98-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gregory Sargen
BRD | Director/Board Member | 59 | 17-11-26 |
Joseph Carleone
CHM | Chairman | 78 | 17-11-26 |
Catherine Mackey
BRD | Director/Board Member | 68 | 19-07-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 9.2 | -0.54% | 790,972 |
24-05-15 | 9.25 | +0.54% | 1,340,740 |
24-05-14 | 9.2 | +4.43% | 1,735,367 |
24-05-13 | 8.81 | +1.61% | 1,081,435 |
24-05-10 | 8.67 | +6.51% | 1,009,478 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.54% | 587M | |
-0.91% | 91.42B | |
+3.16% | 41.08B | |
-11.10% | 34.26B | |
+53.99% | 25.27B | |
-9.41% | 12.81B | |
-12.25% | 11.6B | |
-44.00% | 11.42B | |
+5.77% | 9.16B | |
-6.90% | 8.22B |
- Stock Market
- Equities
- CDMO Stock